4.8 Article

Lowering apolipoprotein CIII protects against high-fat diet-induced metabolic derangements

Journal

SCIENCE ADVANCES
Volume 7, Issue 11, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abc2931

Keywords

-

Funding

  1. Swedish Diabetes Association
  2. Funds of Karolinska Institutet
  3. Swedish Research Council
  4. Novo Nordisk Foundation
  5. Family Erling-Persson Foundation
  6. Strategic Research Program in Diabetes at Karolinska Institutet
  7. Family Knut and Alice Wallenberg Foundation
  8. Stichting af Jochnick Foundation
  9. Skandia Insurance Company Ltd.
  10. Diabetes and Wellness Foundation
  11. Bert von Kantzow Foundation
  12. Svenska Diabetesstiftelsen
  13. AstraZeneca
  14. Swedish Association for Diabetology
  15. ERC-EYLETS [834860]
  16. European Research Council (ERC) [834860] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Lowering apoCIII can protect against and reverse the metabolic phenotype induced by HFD by promoting physiological insulin sensitivity.
Increased levels of apolipoprotein CIII (apoCIII), a key regulator of lipid metabolism, result in obesity-related metabolic derangements. We investigated mechanistically whether lowering or preventing high-fat diet (HFD)-induced increase in apoCIII protects against the detrimental metabolic consequences. Mice, first fed HFD for 10 weeks and thereafter also given an antisense (ASO) to lower apoCIII, already showed reduced levels of apoCIII and metabolic improvements after 4 weeks, despite maintained obesity. Prolonged ASO treatment reversed the metabolic phenotype due to increased lipase activity and receptor-mediated hepatic uptake of lipids. Fatty acids were transferred to the ketogenic pathway, and ketones were used in brown adipose tissue (BAT). This resulted in no fat accumulation and preserved morphology and function of liver and BAT. If ASO treatment started simultaneously with the HFD, mice remained lean and metabolically healthy. Thus, lowering apoCIII protects against and reverses the HFD-induced metabolic phenotype by promoting physiological insulin sensitivity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available